For instance, we showed that the relative expression of (MCL-1 + BFL-1)/BCL-2 was the most significant predictive marker for the response of primary CLL and leukemic cell lines to ABT-737 treatment43. This evidence concerns the gene BCL2A1 and B-cell chronic lymphocytic leukemia.